What's Going On With Vanda Pharmaceuticals Shares Today?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 27 2024
0mins
Source: Benzinga
- Vanda Pharmaceuticals Acquisition Proposal Withdrawn: Future Pak has withdrawn its proposal to purchase Vanda Pharmaceuticals Inc., citing lack of response and rejection of their final offer.
- Stock Performance: Vanda Pharmaceuticals' shares have declined over 9% in the past year, with investors being able to access the stock through Invesco NASDAQ Future Gen 200 ETF QQQS.
- Company's Response: Vanda Pharmaceuticals stated that takeover proposals from Future Pak and Cycle Group undervalued the company, leading to the rejection of these offers by the Board.
- FDA Approval: In April, the FDA approved Vanda Pharmaceuticals' Fanapt tablets for the treatment of manic or mixed episodes associated with bipolar I disorder in adults.
- Current Stock Price: As of the latest check, VNDA shares are trading lower by 1.92% at $5.865.
Analyst Views on VNDA
Wall Street analysts forecast VNDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNDA is 13.63 USD with a low forecast of 7.50 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.100
Low
7.50
Averages
13.63
High
22.00
Current: 8.100
Low
7.50
Averages
13.63
High
22.00
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








